All In Biotech

Drug Trial Radar · NCT03842982

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

362

Planned (sponsor's estimate)

Start

May 3, 2019

Primary completion

Feb 1, 2031

Study completion Feb 1, 2031

Sponsor

Lead sponsor
Centre Oscar LambretAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 76 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.

Conditions

  • Ovary Neoplasms
  • Ovarian Cancer
  • Ovarian Carcinoma

Interventions

  • HIPECDrug

    HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate. Administration of the dose should be according the following schedule: * 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion. * The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS)Time frame: From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium

  • Cliniques universitaires St-Luc, Institut Roi Albert II

    Brussels, Belgium

  • Institut de Cancérologie de l'Ouest

    Angers, France

  • Institut Bergonié

    Bordeaux, France

  • Centre François Baclesse

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Oscar Lambret

    Lille, France

  • Hôpital Jeanne de Flandre

    Lille, France

  • Institut Paoli Calmettes

    Marseille, France

  • ICM-Val d'Aurelle

    Montpellier, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Clinique Mathilde

    Rouen, France

  • Centre Henri Becquerel

    Rouen, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.